CLAIMS:

1. A method of diagnosing a subject as having a coronavirus-induced disease, wherein the disease is characterized by mast cell degranulation, acute inflammation, pulmonary pathology and/or vascular pathology, the method comprising:

(a) obtaining a biological sample from the subject;

(b) determining the level and/or activity of at least one biomarker in the biological sample from the subject, wherein the biomarker is a mast cell protease selected from the group consisting of chymase and tryptase;

(c) comparing the level and/or activity of the at least one biomarker in the biological sample to a reference level and/or activity of the at least one biomarker;

(d) identifying the subject as having the disease or having an increased risk of developing the disease if the level and/or activity of the at least one biomarker is greater than the reference level and/or activity of the at least one biomarker, wherein the reference level and/or activity is from a sample from a healthy patient, a patient having a mild form of the coronavirus-induced disease, or a patient having a severe form of the coronavirus-induced disease, wherein the sample is selected from a group consisting of serum, plasma and saliva, wherein the coronavirus is Severe Acute Respiratory Syndrome-associated coronavirus 2 (SARS-CoV-2).

2. The method of claim 1, wherein:

a) a mast cell protease level and/or activity greater than 1 standard deviation above the mean for patients during acute disease or during disease resolution indicates the subject should be monitored for severe disease and/or complications; or

b) a mast cell protease level above a normal level of about 300 pg/mL for tryptase or 3 ng/mL for chymase indicates the subject should be monitored for severe disease.

3. A method of monitoring the efficacy of a method of treatment of a coronavirus-induced disease, wherein the disease is characterized by mast cell degranulation, acute inflammation, pulmonary pathology, and/or vascular pathology wherein a subject has been administered a composition comprising a mast cell stabilizer and/or inhibitor of mast cell products, wherein;

the mast cell stabilizer is selected from one or more of a group consisting of cromolyn, nedocromil, pemirolast, lodoxamide, tranilast, glucosamine, N-acetylglucosamine, FPL 52694, aloe vera, quercetin, chondroitin sulfate, dehydroleucodine, mast cell stabilizer TF002, rupatadine, loratadine, cetirizine, clemastime, fexofenadine, diphenhydramine, chlorpheniramine, azelastine, olopatadine, naphazoline, ketotifen, emedastine,

ebrotidine, calcium channel blocker, a cytochrome P450 inhibitor, a histamine antagonist,

and the inhibitor of mast cell products is selected from one or more of a group consisting of zafirlukast, ketanserin, montelukast, pranlukast, zileuton, SM-12502, rupatadine, PAF-targeting antibodies, xanthine derivatives, methylxanthines like theophylline oxtriphylline, dyphylline, aminophylline, bupropion, curcumin, catechins, aprotinin, serpin, a chymase inhibitor, TY-51469, chymostatin, leupeptin, APC-336, SUN-C8257, NK3201, RO566852, BCEAB, NK3201, TEI-E548, APC-2095, RWJ-355871, TPC-806, ZIGPFM, AAPF-S-Bzl, Bowman-Birk soybean protease inhibitor, BI-1942, TEI-f00806, BAY-1142524, fulacimstat, ASB17061, Polygonum, SFTI-1 and derivatives, bevacizumab, ranibizumab, lapatinib, sunitinib sorafenib, axitinib, pazopanib, thiazolidinediones, benzoxazole, benzthiazole, benzinidzole, CP105,696, laropiprant, acetylsalicylic acid (ASA), indomethacin, sodium meclofenamate (FEN), phenylbutazone (PB), phloretin phosphates (PP), SC-19220, diethylcarbamazine citrate (DECC), protamine and polybrene, a tryptase inhibitor, nafamostat mesylate, BMS-262084, BMS-363131, BSM-36130, Guanadino β-lactams that inhibit tryptase, delta inhibitors of tryptase, benzamidine dimers that inhibit tryptase, piperidine containing 4-carboxy azetidinone tryptase inhibitors, APC-2059, BAY 443428, phenylglycylcarbonyl benzylamines, Peptidyl heterocyclic ketones, Guanidino Bicyclic lactam, Amino or Amidino dimers, Peptidomimetic inhibitors, MOL-6131, RWJ-56423, RWJ-58643, RWJ-51084, BABIM (bis-(5-amidino-2-benzimidazoyl) methane, APD-8, AMG-126737, 4-chlorobenzyoyl ester of 4-hydroxytetronic acid and its *p*-toluate tetronic acid derivatives, M-58538, AY-0068, PMD-3027, Cyclotheonamide E4 and E5, and amidinobenzofuran derivatives,

comprising serially measuring the level and/or activity of a mast cell protease selected from the group consisting of chymase and tryptase, in at least one sample from said subject,

wherein the sample is selected from a group consisting of serum, plasma and saliva, wherein the coronavirus is SARS-CoV-2.

4. The method of claim 3, wherein said mast cell stabilizer and/or inhibitor of mast cell products are selected from the group consisting of ketotifen [IUPAC Name: 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7] tetradeca-1(14),3(7),4,10,12-pentaen-8-one ], cromolyn [IUPAC Name: 5-[3-(2-carboxy -4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid], nafamostat mesylate [IUPAC Name: (6-carbamimidoylnaphthalen-2-yl) 4-

(diaminomethylideneamino)benzoate;methanesulfonic acid], TY-51469 [IUPAC Name 2-[4-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)sulfonylamino]-3-methylsulfonylphenyl]-1,3-thiazole-4-carboxylic acid] and ketanserin [IUPAC Name: 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione].

5. The method of claim 4, wherein;

-cromolyn is formulated for administration to adults at 200 mg or more 4x a day, and children at 100 mg or more 4x a day;

-ketotifen is formulated for administration orally at 1 mg or more per day in adults or 0.110 mg or more per pound of body weight including for children;

-nafamostat mesylate is formulated for administration at 20-50 mg or more infusion, or 2-10 mg/kg or more per day;

-TY-51469 is formulated for administration at 0.1-100 mg/kg or more per day; and/or

-Ketanserin is formulated for administration at 10-100 mg or more twice a day.

6. Use of a composition for the manufacture of a medicament for the treatment of a coronavirus-induced disease, wherein the disease is characterized by mast cell degranulation, acute inflammation, pulmonary pathology and/or vascular pathology,

wherein the composition comprises a mast cell stabilizer and/or inhibitor of mast cell products, wherein;

the mast cell stabilizer is selected from one or more of a group consisting of cromolyn, nedocromil, pemirolast, lodoxamide, tranilast, glucosamine, N-acetylglucosamine, FPL 52694, aloe vera, quercetin, chondroitin sulfate, dehydroleucodine, mast cell stabilizer TF002, rupatadine, loratadine, cetirizine, clemastime, fexofenadine, diphenhydramine, chlorpheniramine, azelastine, olopatadine, naphazoline, ketotifen, emedastine, ebrotidine, calcium channel blocker, a cytochrome P450 inhibitor, a histamine antagonist,

and the inhibitor of mast cell products is selected from one or more of a group consisting of zafirlukast, ketanserin, montelukast, pranlukast, zileuton, SM-12502, rupatadine, PAF-targeting antibodies, xanthine derivatives, methylxanthines like theophylline oxtriphylline, dyphylline, aminophylline, bupropion, curcumin, catechins, aprotinin, serpin, a chymase inhibitor, TY-51469, chymostatin, leupeptin, APC-336, SUN-C8257, NK3201, RO566852, BCEAB, NK3201, TEI-E548, APC-2095, RWJ-355871, TPC-806, ZIGPFM, AAPF-S-Bzl, Bowman-Birk soybean protease inhibitor, BI-1942, TEI-f00806, BAY-1142524, fulacimstat, ASB17061, Polygonum, SFTI-1 and derivatives, bevacizumab, ranibizumab, lapatinib, sunitinib sorafenib, axitinib, pazopanib, thiazolidinediones, benzoxazole, benzthiazole, benzinidzole, CP105,696, laropiprant, acetylsalicylic acid (ASA),

indomethacin, sodium meclofenamate (FEN), phenylbutazone (PB), phloretin phosphates (PP), SC-19220, diethylcarbamazine citrate (DECC), protamine and polybrene, a tryptase inhibitor, nafamostat mesylate, BMS-262084, BMS-363131, BSM-36130, Guanadino β-lactams that inhibit tryptase, delta inhibitors of tryptase, benzamidine dimers that inhibit tryptase, piperidine containing 4-carboxy azetidinone tryptase inhibitors, APC-2059, BAY 443428, phenylglycylcarbonyl benzylamines, Peptidyl heterocyclic ketones, Guanidino Bicyclic lactam, Amino or Amidino dimers, Peptidomimetic inhibitors, MOL-6131, RWJ-56423, RWJ-58643, RWJ-51084, BABIM (bis-(5-amidino-2-benzimidazoyl) methane, APD-8, AMG-126737, 4-chlorobenzyoyl ester of 4-hydroxytetronic acid and its *p*-toluate tetronic acid derivatives, M-58538, AY-0068, PMD-3027, Cyclotheonamide E4 and E5, and amidinobenzofuran derivatives,

wherein the coronavirus is SARS-CoV-2.

7. The use of claim 6, wherein said mast cell stabilizer and/or inhibitor of mast cell products are selected from the group consisting of ketotifen [IUPAC Name: 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7] tetradeca-1(14),3(7),4,10,12-pentaen-8-one ], cromolyn [IUPAC Name: 5-[3-(2-carboxy -4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid], nafamostat mesylate [IUPAC Name: (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate;methanesulfonic acid], TY-51469 [IUPAC Name 2-[4-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)sulfonylamino]-3-methylsulfonylphenyl]-1,3-thiazole-4-carboxylic acid] and ketanserin [IUPAC Name: 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione].

8. The use of claim 7, wherein the composition comprises:

i) cromolyn formulated for administration at 200 mg or more 4x a day (adults), or at 100 mg or more 4x a day (children);

ii) ketotifen formulated for administration at 1 mg or more per day (adults) or at 0.110 mg or more per pound of body weight (adults or children);

iii) nafamostat, formulated for administration at 20-50 mg or more by infusion, or 2-10 mg/kg or more per day;

iv) TY-51469, formulated for administration at 0.1-100 mg/kg or more per day; and/or

v) Ketanserin, and is formulated for administration at 10-100 mg or more twice a day.

9. The use of claim 6, wherein the composition comprises:

a) ketotifen and indomethacin;

b) ketotifen and loratadine;

c) ketotifen and fexofenadine;

d) ketotifen and cetirizine;

e) cromolyn and indomethacin;

f) cromolyn and loratadine;

g) cromolyn and fexofenadine; or

h) cromolyn and cetirizine.